Johnson & Johnson (NYSE:JNJ) Price Target Raised to $166.00

Johnson & Johnson (NYSE:JNJ) had its price objective raised by Barclays from $159.00 to $166.00 in a research note published on Tuesday morning,Benzinga reports. The brokerage currently has an equal weight rating on the stock.

JNJ has been the subject of several other research reports. Wolfe Research began coverage on shares of Johnson & Johnson in a research report on Friday, November 15th. They set an “outperform” rating and a $190.00 price objective for the company. Cantor Fitzgerald restated an “overweight” rating and issued a $215.00 price target on shares of Johnson & Johnson in a research report on Wednesday, October 16th. Guggenheim raised their price objective on Johnson & Johnson from $156.00 to $162.00 and gave the stock a “neutral” rating in a research note on Wednesday, November 6th. Wells Fargo & Company cut their target price on Johnson & Johnson from $166.00 to $152.00 and set an “equal weight” rating on the stock in a research report on Thursday, January 23rd. Finally, Raymond James dropped their price target on Johnson & Johnson from $170.00 to $165.00 and set an “outperform” rating on the stock in a research note on Thursday, January 23rd. Nine equities research analysts have rated the stock with a hold rating, eight have issued a buy rating and two have issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, Johnson & Johnson presently has an average rating of “Moderate Buy” and an average price target of $170.44.

Johnson & Johnson Trading Up 1.1 %

NYSE:JNJ opened at $152.78 on Tuesday. Johnson & Johnson has a 1 year low of $140.68 and a 1 year high of $168.85. The business has a fifty day moving average of $147.73 and a 200-day moving average of $156.10. The company has a debt-to-equity ratio of 0.45, a quick ratio of 0.79 and a current ratio of 1.03. The stock has a market cap of $367.82 billion, a price-to-earnings ratio of 22.97, a PEG ratio of 2.45 and a beta of 0.51.

Johnson & Johnson (NYSE:JNJ) last released its earnings results on Wednesday, January 22nd. The company reported $2.04 EPS for the quarter, beating the consensus estimate of $1.99 by $0.05. The firm had revenue of $22.52 billion for the quarter, compared to analysts’ expectations of $22.44 billion. Johnson & Johnson had a net margin of 18.20% and a return on equity of 34.35%. Johnson & Johnson’s quarterly revenue was up 5.3% on a year-over-year basis. During the same quarter last year, the company earned $2.29 EPS. Equities analysts predict that Johnson & Johnson will post 10.56 earnings per share for the current year.

Johnson & Johnson Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 4th. Investors of record on Tuesday, February 18th will be issued a dividend of $1.24 per share. The ex-dividend date is Tuesday, February 18th. This represents a $4.96 annualized dividend and a dividend yield of 3.25%. Johnson & Johnson’s dividend payout ratio is 74.59%.

Insider Buying and Selling at Johnson & Johnson

In other news, Director Mark A. Weinberger purchased 1,000 shares of the stock in a transaction that occurred on Thursday, December 12th. The stock was acquired at an average price of $147.22 per share, with a total value of $147,220.00. Following the purchase, the director now owns 1,000 shares in the company, valued at $147,220. This represents a ∞ increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Corporate insiders own 0.16% of the company’s stock.

Institutional Trading of Johnson & Johnson

Large investors have recently added to or reduced their stakes in the business. IFS Advisors LLC increased its position in Johnson & Johnson by 138.9% during the fourth quarter. IFS Advisors LLC now owns 172 shares of the company’s stock worth $25,000 after buying an additional 100 shares during the last quarter. Highline Wealth Partners LLC acquired a new position in shares of Johnson & Johnson during the 3rd quarter valued at about $31,000. Bay Harbor Wealth Management LLC acquired a new stake in Johnson & Johnson in the 4th quarter worth approximately $32,000. RPg Family Wealth Advisory LLC bought a new stake in Johnson & Johnson during the third quarter worth approximately $35,000. Finally, Mowery & Schoenfeld Wealth Management LLC raised its position in shares of Johnson & Johnson by 58.7% in the third quarter. Mowery & Schoenfeld Wealth Management LLC now owns 246 shares of the company’s stock valued at $40,000 after purchasing an additional 91 shares during the period. 69.55% of the stock is owned by institutional investors.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.